AUPH as reported
Aurinia Pharmaceuticals Inc. reported $298M of revenue over the trailing twelve months, +21% on the year before. 9 reported series are charted on this page, each one as filed.
$298M
Revenue, trailing twelve months · to Q1 2026 · +21% against the twelve months before
- Net Income
- $298M
Net Income · +648% year on year · trailing twelve months to Q1 2026
- Op Margin
- 41%
Op Margin · trailing twelve months to Q1 2026
- EPS
- $2.17
EPS · +675% year on year · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $298M | +21% | Q1 2026 |
| Net Income | $298M | +648% | Q1 2026 |
| EPS | $2.17 | +675% | Q1 2026 |
| Gross Margin | 90% | n/a | Q1 2026 |
| Op Margin | 41% | n/a | Q1 2026 |
| Net Margin | 98% | n/a | Q1 2026 |
| ROE | 35% | n/a | Q1 2026 |
| ROA | 27% | n/a | Q1 2026 |
| P/E | 7.62 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Aurinia Pharmaceuticals Inc. (AUPH) - Revenue & ProfitRevenue & ProfitAurinia Pharmaceuticals Inc. (AUPH)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com